Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PDL BioPharma names new director of Facet Biotech
Since September 2007, Dr Parkinson has served as president and CEO of Nodality, a South San Francisco, California-based biotechnology company. Dr Parkinson has received his MD degree from
Since September 2007, Dr Parkinson has served as president and CEO of Nodality, a South San Francisco, California-based biotechnology company. Dr Parkinson has received his MD degree from
This double-blinded, placebo controlled trial will assess safety and efficacy of Prochymal over a six-month period. A total of 244 patients were enrolled at 72 leading bone marrow
Robert Peterson, Hemispherx’s CFO for approximately 20 years, is retiring at that time; he will retain a position of consultant and financial advisor to the company. Mr Bernhardt
The pilot study is being conducted at four sites: VA Boston Healthcare System; VA New Jersey Healthcare System; Vanderbilt University Medical Center, Department of Urologic Surgery; and The
According to the company, the new office in Munich provides proximity to major pharmaceutical companies operating in and around that city, as well as access to the area’s
The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late stage cancer. VTX-2337 is a small molecule TLR8 agonist
The license will enable Astellas to more efficiently produce its drug targets, such as antibodies in mammalian cells, by generating higher protein yields. Financial terms were not disclosed.
Mr Bertocci, who has been serving as the CFO of BioForm Medical, a publicly-traded medical aesthetics company headquartered in San Mateo, California, since October 2006, will begin at
GS9411 is designed to increase airway hydration for the treatment of pulmonary disease. Previously known as P-680, GS9411 is an epithelial sodium channel (ENaC) blocker discovered by Parion.
Under the terms of the agreement, Azur paid BioSante $3.3 million comprised of a product licensing fee and payment for the transfer of the trademark and inventories, amongst